Our business delivered healthy results in Q2, led by MAU and Subscriber outperformance, Y/Y profitability improvement and strong Free Cash Flow* generation. The business added 18 million MAU in Q2 vs. guidance for 11 million, while Subscriber net additions of 8 million exceeded guidance by 3 million. Revenue grew 15% Y/Y on a constant currency* basis reflecting Premium and Ad-Supported growth. Outsized currency movements during the quarter impacted reported Revenue by €104 million vs. guidance. Gross Margin ...

Financial Performance - Total revenue reached $758 million[12], with cloud communications revenue accounting for $552 million[12] - Cloud communications revenue experienced a year-over-year growth of 10%[12] - Adjusted EBITDA grew by 36% year-over-year, reaching $91 million[12] - Free cash flow increased by 26% year-over-year, totaling $57 million[12] Revenue Growth - Total revenue grew by 15% year-over-year[12] - 2Q25 total revenue growth was 9% year-over-year, normalized for campaign messaging revenue[19, 21] - 2Q25 cloud communications revenue growth was 8% year-over-year, normalized for campaign messaging revenue[19, 21] Customer Metrics - The company maintained strong customer loyalty, with a top 20 customer median tenure of 11 years[16] - Net Retention Rate was 112%[16, 38] - Average annual customer revenue increased by 16% year-over-year[38] Gross Margin and EBITDA - Non-GAAP gross margin expanded, reaching 59% in the first half of 2025[24] - 2Q25 Adjusted EBITDA grew by 17% year-over-year[28] - 2Q25 Adjusted EBITDA margin was 16%[28] Future Outlook - The company raised its full-year 2025 EBITDA guidance[42] - The company expects approximately 10% total revenue growth year-over-year for 2025, normalized for political campaign revenue[42, 43, 44, 46]

Second Quarter 2025 Financial Results July 29, 2025 1 Cautionary Note Regarding Forward-Looking Statements Forward-looking statements are not guarantees of future performance and are subject to risks that could cause actual results to differ materially from those expressed or implied in such forward-looking statements, including, among others, risks related to: customer and segment concentration; reduction in customer revenue; erosion in customer market competitiveness; changing revenue mix and margins; unc ...

Core Viewpoint - Hoth Therapeutics, Inc. is expanding its Phase II clinical trial for HT-001, targeting cancer patients with skin toxicities related to Epidermal Growth Factor Receptor Inhibitors (EGFRi) in the European Union [1][2][3] Group 1: Clinical Trial Expansion - The company is engaging with ICON Clinical Research Limited to broaden its Phase II clinical trial in EU countries [1][2] - Additional regulatory approval for the trial is anticipated from potentially three EU countries in the coming months [2] - The trial is currently enrolling patients at multiple sites in the United States, focusing on the efficacy, safety, and tolerability of topical HT-001 [2] Group 2: Strategic Goals - The CEO of Hoth Therapeutics expressed satisfaction with the partnership with ICON, highlighting their experience in clinical trial management and interest in novel therapies [3] - Expanding clinical sites in the EU aims to complete enrollment for the Phase II trial and lays the groundwork for a future global Phase III trial [3] Group 3: Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments to enhance patient quality of life [4] - The company collaborates with scientists, clinicians, and key opinion leaders to explore therapeutics with significant potential [4]

市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何 意见、观点或结论是否符合其特定状况。据此投资，责任自负。 风险提示及免责条款 微软正与OpenAI展开深入谈判，以达成一项使其能够持续获取关键OpenAI技术的协议。据两位知情人 士透露，两家公司已经讨论了将允许微软使用OpenAI最新模型和相关技术的新条款，即使OpenAI认为 其已达成开发更强大人工智能，即"通用人工智能"(AGI)的目标。根据现有合同，OpenAI达到AGI水平 被视为一个关键里程碑，届时微软将失去对OpenAI技术的部分权利。谈判人员定期会面，协议可能在 几周内敲定。OpenAI首席执行官Sam Altman与微软首席执行官Satya Nadella本月早些时候在爱达荷州太 阳谷举行的Allen & Co.会议上讨论了相关事宜。（彭博） ...

Group 1 - The company is engaged in advanced discussions for potential transactions involving its defence business and the overall balance of the company [1][2] - The Board of Directors is carefully reviewing these potential transactions while considering the interests of all stakeholders, including shareholders, employees, and clients [2] - Iveco Group operates under seven major brands, including IVECO, FPT Industrial, IVECO BUS, HEULIEZ, IDV, ASTRA, and IVECO CAPITAL, employing 36,000 people globally with 19 industrial sites and 31 R&D centres [3]

Core Viewpoint - Atossa Therapeutics has received positive feedback from the FDA regarding its proposed dose optimization trial for (Z)-endoxifen, aimed at treating ER+/HER2- metastatic breast cancer, which is a significant milestone for the company [1][2][3] FDA Feedback and Clinical Development - The FDA's constructive responses affirm key elements of Atossa's clinical development plan, eliminating the need for a virtual pre-IND meeting and facilitating a potential IND submission by Q4 2025 [2][3] - The FDA supports Atossa's dose optimization strategy and agrees with the existing clinical and nonclinical data, allowing the initiation of Part A (monotherapy) of the proposed study [7] Strategic Momentum and Future Plans - Atossa is positioned to maintain strategic momentum and meet regulatory milestones, aiming to deliver (Z)-endoxifen to patients and enhance shareholder value [5] - The company plans to announce details regarding the target patient population, combination therapies, and overall trial design for the upcoming dose-ranging study in the coming weeks [7] Project Optimus and Dose Exploration - The FDA's Project Optimus initiative emphasizes data-driven dose exploration to maximize benefits and minimize toxicity, which aligns with Atossa's upcoming clinical study plans [6] - Atossa will explore multiple dose levels in its study to define the optimal dose for combination therapy while ensuring a balance between efficacy and patient safety [6] (Z)-Endoxifen Overview - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator (SERM) that inhibits and potentially degrades estrogen receptors, showing activity in tumors resistant to other therapies [8] - The compound is being developed in a proprietary oral formulation that is enteric-coated to ensure optimal bioavailability and therapeutic integrity [9] Clinical Trials and Intellectual Property - Atossa is prioritizing (Z)-endoxifen for metastatic breast cancer, currently evaluating it in three Phase 2 trials [10] - The program is supported by a growing global intellectual property portfolio, including recently issued U.S. patents and pending applications worldwide [10]

Core Viewpoint - Atossa Therapeutics has received positive feedback from the FDA regarding its proposed dose optimization trial for (Z)-endoxifen, aimed at treating ER+/HER2- metastatic breast cancer, which is a significant milestone for the company [1][2][3] FDA Feedback and Clinical Development - The FDA's constructive responses affirm key elements of Atossa's clinical development plan, eliminating the need for a virtual pre-IND meeting and facilitating a potential IND submission by Q4 2025 [2][3] - The FDA supports Atossa's dose optimization strategy and agrees with the existing nonclinical data package, enhancing confidence in the company's regulatory approach [3][7] Dose Optimization Strategy - The FDA has confirmed that existing clinical and nonclinical data are sufficient to initiate Part A (monotherapy) of the proposed dose optimization study, providing guidance on study design enhancements [7] - Atossa plans to explore multiple dose levels in its upcoming clinical study to define the optimal dose for combination therapy, aligning with the FDA's Project Optimus initiative [6][7] Combination Study Support - The FDA agrees with the scientific rationale for combining (Z)-endoxifen with standard-of-care therapies for breast cancer, which helps narrow the strategic approach for the potential IND [7] Cardiac Safety and Nonclinical Data - The FDA has confirmed that Atossa's cardiac safety assessment plan, including ECGs and QT interval monitoring, is sufficient for the monotherapy portion of the trial [7] - The existing nonclinical safety data package is deemed adequate, allowing Atossa to proceed without additional toxicity studies [7] Next Steps and Strategic Momentum - Atossa will announce plans for the target patient population, combination backbone, and overall trial design for the upcoming dose-ranging study in the coming weeks [7] - The company is positioned to maintain strategic momentum and meet regulatory milestones, aiming to deliver (Z)-endoxifen to patients and enhance shareholder value [5][10] About (Z)-Endoxifen - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator (SERM) that inhibits and potentially degrades estrogen receptors, showing activity in tumors resistant to other therapies [8][10] - Atossa is developing an oral formulation of (Z)-endoxifen that is enteric-coated to ensure optimal bioavailability and therapeutic integrity [9] Clinical Trials and Intellectual Property - Atossa is prioritizing (Z)-endoxifen for metastatic breast cancer, currently evaluating it in three Phase 2 trials [10] - The program is supported by a growing global intellectual property portfolio, including recently issued U.S. patents [10]

Core Viewpoint - Jacobs has been selected to provide program management support for the Consolidated Rent-A-Car Facility (ConRAC) and Common Transportation System (CTS) at Denver International Airport (DEN), which is part of a broader capital improvement initiative aimed at enhancing safety, passenger experience, and operational efficiency while promoting sustainable aviation [1][2]. Group 1: Project Details - The ConRAC and CTS projects are essential for DEN's projected growth, with expectations to exceed 120 million passengers by 2045, facilitating a seamless rental car experience for travelers [2]. - The consolidation of rental car operations into a single facility will reduce terminal area traffic, eliminate excessive shuttle buses, and free up curb space for future redevelopment [3]. Group 2: Jacobs' Expertise and Contributions - Jacobs will leverage its global program management experience and specific knowledge in electric vehicle infrastructure, fueling operations, traffic design, and customer interface technologies to support the airport's capacity expansion while minimizing environmental impact [3]. - The company has a long-standing relationship with DEN, having delivered over 60 critical projects since 1992, including the Great Hall Improvement Program and Concourse Expansion Program [4]. Group 3: Industry Position - Jacobs is ranked No. 2 in Transportation by Engineering News-Record and provides comprehensive services in transportation infrastructure, helping clients move people and goods across various modes of transport [5]. - The company generates approximately $12 billion in annual revenue and employs nearly 45,000 people, focusing on creating a more connected and sustainable world through its diverse service offerings [6].

三、以点带面，彰显数字赋能实效 日照经开区以数字化为重要引擎，通过系列创新实践，让数字技术深度融入教育教学各环节，为教育高 质量发展插上智慧的翅膀，引领全区教育向高质量发展。在全省2025年数字化赋能教育高质量发展应用 典型案例征集中，3个应用案例入围省级评选，1个案例入选全省数字化赋能教育高质量发展应用典型案 例集，打造经开区数字赋能教育高质量发展的亮丽名片。 数字化赋能不仅改变了教学与评价模式，更在推动教育均衡、提升全区教育质量发展方面展现了巨大的 作用，充分发挥5所强校扩优核心学校的引领带动作用，通过数字化手段，使优质教育资源高效流转， 缩小校际差距，促进教育公平。经开区实验学校推荐的《智慧闯关+精准画像：数字化赋能一二年级乐 考的高质量发展范例》入选省级典型案例，是对经开区数字赋能教育实践的高度认可，也为其他学校提 供了可借鉴的先进经验。 二、学段贯通，构建数字化教育生态 立足不同学段学生的成长特点，构建起覆盖幼小中的全学段数字化教育生态，让数字化赋能贯穿学生成 长的关键阶段。学前教育阶段，"数智融合"多元场景构建覆盖家校社协同、教师发展、幼儿成长记录等 场景的数字化生态，激发幼儿学习兴趣和探索欲；一 ...